Cowen & Co. Thinks Urogen Pharma Ltd’s Stock is Going to Recover

By Austin Angelo

In a report released today, Boris Peaker from Cowen & Co. maintained a Buy rating on Urogen Pharma Ltd (URGNResearch Report). The company’s shares opened today at $36.14, close to its 52-week low of $34.61.

According to, Peaker is a 4-star analyst with an average return of 3.6% and a 41.7% success rate. Peaker covers the Healthcare sector, focusing on stocks such as Stemline Therapeutics Inc, CytomX Therapeutics Inc, and Jounce Therapeutics Inc.

Urogen Pharma Ltd has an analyst consensus of Strong Buy, with a price target consensus of $66.25, implying an 83.3% upside from current levels. In a report issued on April 24, H.C. Wainwright also reiterated a Buy rating on the stock with a $75 price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $69.57 and a one-year low of $34.61. Currently, Urogen Pharma Ltd has an average volume of 121.6K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

UroGen Pharma Ltd. is a clinical stage pharmaceutical company, which engages in the provision of non-surgical and localized solutions for urological pathologies to address a clinical unmet need in field of uro-oncology.